What Is Your Medspa Worth? Valuation & EBITDA Multiples

Medspa valuations cluster into three tiers. Small independent practices (typically $500K–$2M revenue, single location, owner-operator model) trade at 3–5x EBITDA. These are high-risk acquisitions for buyers: customer concentration, key-person dependency, and limited systems. Established regional practices ($2M–$10M revenue, multiple locations or strong brand, professional management layer) command 6–10x EBITDA. They have recurring patient bases, documented procedures, and some operational redundancy. Platform/roll-up targets ($10M+ revenue, multi-location, scalable operations, strong margins) reach 12–20x EBITDA or higher—especially if they're acquisition vehicles for PE firms buying up smaller competitors. The multiple reflects buyer confidence in cash-flow predictability and growth runway. A practice with 40% EBITDA margins and 70% patient retention will command a premium within its tier; one with 15% margins and high churn will sit at the floor.

Recurring revenue and retention are the primary levers. Medspas with high-touch loyalty programs, subscription models (e.g., monthly injectables or membership plans), and documented patient lifetime value justify higher multiples because cash flow is predictable. Gross margins matter enormously. Practices with strong toxin/filler purchasing power (via Alle, Aspire, or Evolus Rewards rebate programs) and efficient supply chains show 50%+ gross margins; those with weak negotiating position or high waste sit at 30–40%. Buyers model out the margin and assume it persists. Staffing and systems reduce key-person risk. A practice with documented protocols, trained injectors, and a non-owner manager is worth more than one where the owner is the only revenue driver. Patient acquisition cost and payback also factor in. If you're spending 5% of revenue on marketing with a 6-month payback, that's attractive; if it's 15% with 18-month payback, the multiple compresses. Geographic location and real estate matter: a practice in a high-income zip code with owned or long-term-leased space is less risky than one in a declining area or on a month-to-month lease.

Not all purchase prices are created equal. All-cash deals at a stated multiple are rare and usually signal a distressed sale or a buyer with excess capital. More common is a blended structure: 60–70% cash at close, with the remainder as a seller note (typically 2–3 year term at 5–7% interest) or earnout tied to post-close EBITDA or patient retention. Earnouts are popular in medspa deals because they align seller and buyer incentives during transition. If you agree to a $5M valuation with a $3M cash payment and $2M earnout over two years, you're betting the practice maintains or grows EBITDA—which you control. Rollover equity (where you retain a minority stake and participate in upside) is common in platform acquisitions. A buyer might offer 6x EBITDA in cash plus the opportunity to roll 10–20% equity into the platform at a higher implied valuation, giving you exposure to the roll-up's growth. Always clarify: is the multiple pre- or post-transaction costs? Are you paying reps and warranties insurance? What happens to working capital?

When you receive a term sheet, extract these numbers first. Enterprise Value (EV) is the headline; divide it by your trailing 12-month EBITDA to get the multiple. Adjust EBITDA for one-time items (owner bonuses, unusual rent, non-recurring marketing spend) so you're comparing apples to apples. Cash at close is what you actually receive; earnouts and seller notes are contingent and illiquid. Calculate the present value of deferred payments using a 10% discount rate to compare offers fairly. Reps and warranties (your legal guarantees about the business) often come with a holdback—typically 10–15% of purchase price, held in escrow for 12–18 months to cover breaches. Understand what you're warranting: patient data accuracy, no pending litigation, compliance with state regulations. Non-compete and non-solicitation terms matter; if you're restricted from practicing within 5 miles for 3 years, that's a material constraint on your next move. Transition services: will you stay on for 90 days? Six months? At what rate? Buyers often want you embedded during handoff to retain patients.

Before you talk to a broker or receive an offer, run your own numbers. Calculate trailing 12-month EBITDA: take net income and add back owner compensation (salary + distributions), interest, taxes, depreciation, and one-time expenses. This is what a buyer will model. Gross margin by service line: toxin, filler, laser/RF, injectables, skincare. Buyers want to see which services are most profitable and which are cash drains. Patient acquisition cost: divide annual marketing spend by new patients acquired. Patient lifetime value: average revenue per patient × average retention (in years). If your LTV is 3x CAC, you're in good shape; if it's 1.5x, growth is expensive. Revenue concentration: what % comes from your top 10 patients? Top procedure? If more than 20% of revenue is one patient or one service, that's a concentration risk that will compress your multiple. Staffing cost as % of revenue: should be 25–35% for a healthy practice. If you're north of 40%, margins are thin. Document all of this in a simple spreadsheet; it's the foundation of any valuation conversation.

Strategic buyers (larger medspa chains, dermatology groups, or PE-backed platforms like those consolidating the aesthetics space) typically pay higher multiples because they can cut costs post-acquisition—consolidate marketing, leverage purchasing power with manufacturers like AbbVie/Allergan, Galderma, or Evolus, eliminate redundant overhead. They're buying EBITDA and synergies. Financial buyers (PE firms, family offices) are buying cash flow and growth potential; they'll pay a fair multiple but expect you to have clean operations and a clear path to margin expansion. A strategic buyer might pay 8x EBITDA for a $3M EBITDA practice; a financial buyer might offer 6.5x. The trade-off: strategics often want you to stay and run the practice post-close (which can be good or bad); financials may bring in a new operator, freeing you up but reducing your control. Understand who's across the table and what they're really buying.